<DOC>
	<DOCNO>NCT02579096</DOCNO>
	<brief_summary>This trial compare two effective therapy , allopurinol febuxostat , low serum uric acid therefore prevent gout attache . These therapy never compare appropriate dos . Further , study patient kidney disease first time .</brief_summary>
	<brief_title>Gout : Allopurinol vs. Febuxostat</brief_title>
	<detailed_description>Gout common form inflammatory arthritis affect adult ( 1 ) , disease frequency continue increase dramatically ( 2 ) . Gout associate substantial morbidity mortality concentrate old men magnify patient chronic kidney disease ( CKD ) ( 3-6 ) , demographic common Veterans Affairs ( VA ) Health System . Effective gout therapy readily available center primarily use approved urate lower therapy ( ULT ) . Despite excellent ULT option available patient ( 7 ) , gout extremely poorly manage especially patient CKD ( 8-10 ) . The two widely use ULTs clinical practice , allopurinol febuxostat , recently endorse two acceptable first-line treatment strategy chronic gout ( 7 ) . Although agent appear efficacious generally well-tolerated , allopurinol febuxostat significantly different cost never compare appropriate dos . Randomized controlled trial complete date compare allopurinol febuxostat gout use 'fixed ' , many case , insufficient dos allopurinol ( 11-13 ) , approach contrary current guideline recommendation ( 7 ) . Furthermore , study include small proportion gout patient CKD even though CKD present approximately 1 every 2 gout sufferer ( 14 ) . To test hypothesis allopurinol non-inferior febuxostat treatment gout , investigator propose randomize open-label non-inferiority trial , first time compare allopurinol febuxostat use appropriately titrate dose `` treat-to-target '' approach . Further , investigator assess comparative effectiveness agent significant number gout patient co-morbid CKD . The investigator plan enroll 950 participant diagnosis gout , include participant stage 3 CKD , hyperuricemic define serum uric acid concentration ( sUA ) 6.8 mg/dl . Participants recruit 18 Veteran Affairs 5 Rheumatology Arthritis Investigational Network ( RAIN ) sit . The total duration trial 4 year . Recruitment occur 24 month . Participants follow 72 week . This include 24 week Dose Titration Phase ( Phase 1 ) follow 24 week Maintenance Optimization Phase ( Phase 2 ) 24 week Steady State Flare Observation Phase ( Phase 3 ) . The investigator use `` treat-to-target '' approach specify titration ULT dose obtain goal sUA . Maximal daily drug dose 800 mg/day allopurinol 120 mg/day febuxostat . The primary outcome proportion participant least one gout flare allopurinol group compare febuxostat group Phase 3 . This primary outcome endorse patient VA provider group survey ( see ) . All participant follow Phase 3 regardless achievement sUA goal . The primary hypothesis test non-inferiority allopurinol regard proportion flare . The investigator anticipate approximately 15 20 % patient flare Phase 3 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Uric Acid</mesh_term>
	<criteria>Age 18 year History gout crystal proven historical define ACR criterion list Serum urate level 6.8 mg/dl Stage 4 5 Chronic Kidney Disease ( CKD ) define eGFR &lt; 30 ml/min Women le 50 year age Patients history prior solid organ / hematopoietic transplantation Previous allergy intolerance allopurinol febuxostat Patients candidate recommend prophylactic medication ( colchicine , naprosyn glucocorticoid ) Previous history failure reach target uric acid level despite therapy allopurinol dose &gt; 300 mg/day Prior febuxostat use Patients malignancy currently active exception nonmelanoma skin cancer Patients serum uric acid level &gt; 15 mg/dl Patients myelodysplasia hemoglobin &lt; 8.5 g/dL Patients chronic liver disease one following : INR 1.7 , Warfarin therapy Bilirubin 2 mg/dL Serum albumin &lt; 3.5 g/dL Ascites Encephalopathy Current use azathioprine , mercaptopurine , didanosine , cyclophosphamide , probenecid Patient unable give inform consent Enrollment another randomize interventional clinical trial Any severe medical condition , enrollee 's opinion , likely compromise participant 's ability complete trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gout</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Febuxostat</keyword>
	<keyword>CKD</keyword>
</DOC>